Schwarze Vincent, Rübenthaler Johannes, Marschner Constantin, Fabritius Matthias Philipp, Rueckel Johannes, Fink Nicola, Puhr-Westerheide Daniel, Gresser Eva, Froelich Matthias Frank, Schnitzer Moritz Ludwig, Große Hokamp Nils, Afat Saif, Staehler Michael, Geyer Thomas, Clevert Dirk-André
Department of Radiology, University Hospital LMU, Marchioninistrasse 15, 81377 Munich, Germany.
Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.
Cancers (Basel). 2020 Sep 30;12(10):2821. doi: 10.3390/cancers12102821.
Fusion imaging depicts an innovative technique that facilitates combining assets and reducing restrictions of advanced ultrasound and cross-sectional imaging. The purpose of the present retrospective study was to evaluate the role of fusion imaging for assessing hepatic and renal lesions. Between 02/2011-08/2020, 92 patients in total were included in the study, of which 32 patients had hepatic lesions, 60 patients had renal lesions. Fusion imaging was technically successful in all patients. No adverse side effects upon intravenous (i.v.) application of (, Milan, Italy) were registered. Fusion imaging could clarify all 11 (100%) initially as indeterminate described hepatic lesions by computed tomography/magnetic resonance imaging (CT/MRI). Moreover, 5/14 (36%) initially suspicious hepatic lesions could be validated by fusion imaging, whereas in 8/14 (57%), malignant morphology was disproved. Moreover, fusion imaging allowed for the clarification of 29/30 (97%) renal lesions initially characterized as suspicious by CT/MRI, of which 19/30 (63%) underwent renal surgery, histopathology revealed malignancy in 16/19 (84%), and benignity in 3/19 (16%). Indeterminate findings could be elucidated by fusion imaging in 20/20 (100%) renal lesions. Its accessibility and repeatability, even during pregnancy and in childhood, its cost-effectiveness, and its excellent safety profile, make fusion imaging a promising instrument for the thorough evaluation of hepatic and renal lesions in the future.
融合成像描绘了一种创新技术,该技术有助于整合资源并减少先进超声和断层成像的限制。本回顾性研究的目的是评估融合成像在评估肝脏和肾脏病变中的作用。在2011年2月至2020年8月期间,共有92例患者纳入研究,其中32例患者有肝脏病变,60例患者有肾脏病变。融合成像在所有患者中技术上均获成功。静脉注射(意大利米兰)后未记录到不良副作用。融合成像能够明确所有11例(100%)最初经计算机断层扫描/磁共振成像(CT/MRI)描述为不确定的肝脏病变。此外,5/14例(36%)最初可疑的肝脏病变可通过融合成像得到证实,而在8/14例(57%)中,恶性形态被排除。此外,融合成像能够明确29/30例(97%)最初经CT/MRI描述为可疑的肾脏病变,其中19/30例(63%)接受了肾脏手术,组织病理学显示16/19例(84%)为恶性,3/19例(16%)为良性。20/20例(100%)肾脏病变中的不确定结果可通过融合成像得以阐明。其可及性和可重复性,即使在孕期和儿童期也是如此,其成本效益以及出色的安全性,使得融合成像成为未来全面评估肝脏和肾脏病变的一种有前景的工具。